Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

BACKGROUND: Ofatumumab is a high-efficacy disease-modifying therapy (DMT) approved for first-line treatment of relapsing-remitting multiple sclerosis (RRMS) in Canada. OBJECTIVE: The aim of this study was to evaluate the cost effectiveness of ofatumumab from a Canadian healthcare system perspective....

Descripción completa

Detalles Bibliográficos
Autores principales: Baharnoori, Moogeh, Bhan, Virender, Clift, Fraser, Thomas, Kimberly, Mouallif, Soukaïna, Adlard, Nicholas, Cooney, Philip, Blanchette, François, Patel, Barkha P., Grima, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596641/
https://www.ncbi.nlm.nih.gov/pubmed/36107307
http://dx.doi.org/10.1007/s41669-022-00363-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596641/
https://www.ncbi.nlm.nih.gov/pubmed/36107307
http://dx.doi.org/10.1007/s41669-022-00363-1

Ejemplares similares